Uridine supplementation with Mitocnol antagonizes antiretroviral nucleoside analogue-induced mitochondrial peripheral and cerebral neuropathy in vivo

Table 1

	Control	Mitocnol	Zidovudine (100 mg/kg/d)	Zidovudine (100 mg/kg/d) + Mitocnol	Zalcitabine (13 mg/kg/d)	Zalcitabine (13 mg/kg/d) + Mitocnol
Ischiadic nerve
mtDNA copies ‡	374 ± 49	372 ± 38	290 ± 65*	346 ± 35†	237 ± 61**	335 ± 48*†
Hippocampus
mtDNA copies ‡	211 ± 51	219 ± 80	104 ± 32**	145 ± 21*†	151 ± 30*	181 ± 53*
COX activity @	11 ± 3	9 ± 3	4 ± 2**	6 ± 2**†	5 ± 2**	8 ± 3*†
COX/SDH-ratio %	100 ± 9	107 ± 9	48 ± 19**	90 ± 18††	50 ± 15**	92 ± 20††
Citrate activity @	1152 ± 201	1086 ± 179	1124 ± 275	1265 ± 314	1791 ± 33*	1361 ± 173*†
COX II/COX IV-ratio %	100 ± 5	122 ± 26	57 ± 25**	89 ± 22†	45 ± 20**	94 ± 20††

*, p < 0.05 vs. controls; † vs. no Mitocnol. **, p < 0.001 vs. control; †† vs. no Mitocnol; %, of control; ‡, copies/nucleus; @, μmoles/min/g protein.